CN114364796A - 嵌合蛋白 - Google Patents

嵌合蛋白 Download PDF

Info

Publication number
CN114364796A
CN114364796A CN202080058906.2A CN202080058906A CN114364796A CN 114364796 A CN114364796 A CN 114364796A CN 202080058906 A CN202080058906 A CN 202080058906A CN 114364796 A CN114364796 A CN 114364796A
Authority
CN
China
Prior art keywords
seq
chimeric protein
nucleotide sequence
amino acid
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080058906.2A
Other languages
English (en)
Other versions
CN114364796B (zh
Inventor
焦娇
王震
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of CN114364796A publication Critical patent/CN114364796A/zh
Application granted granted Critical
Publication of CN114364796B publication Critical patent/CN114364796B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及一种新型嵌合蛋白，所述嵌合蛋白包含第一多肽链和第二多肽链，所述第一多肽链包含凝血因子、和免疫球蛋白的Fc结构域的第一Fc变体，所述第二多肽链包含所述免疫球蛋白的Fc结构域的第二Fc变体，所述第一Fc变体和所述第二Fc变体包含FcRn结合位点。本发明的嵌合蛋白具有凝血因子活性以及延长的半衰期，可用于出血疾病，如血友病的治疗。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080058906.2A 2019-09-02 2020-09-01 嵌合蛋白 Active CN114364796B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108225203 2019-09-02
CN201910822520 2019-09-02
PCT/CN2020/112835 WO2021043127A1 (zh) 2019-09-02 2020-09-01 嵌合蛋白

Publications (2)

Publication Number Publication Date
CN114364796A true CN114364796A (zh) 2022-04-15
CN114364796B CN114364796B (zh) 2023-07-11

Family

ID=74853063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058906.2A Active CN114364796B (zh) 2019-09-02 2020-09-01 嵌合蛋白

Country Status (2)

Country Link
CN (1) CN114364796B (zh)
WO (1) WO2021043127A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
CN104661674A (zh) * 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CA3059662A1 (en) * 2016-08-19 2018-02-22 Ampsource Biopharma Inc. Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof
WO2018102760A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015525222A (ja) * 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180439A (zh) * 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
CN104661674A (zh) * 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CA3059662A1 (en) * 2016-08-19 2018-02-22 Ampsource Biopharma Inc. Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof
WO2018102760A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLUMBERG RS ET AL.: "IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia", 《BLOOD》 *
LEVIN D ET AL.: "Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model", 《JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH》 *

Also Published As

Publication number Publication date
WO2021043127A1 (zh) 2021-03-11
CN114364796B (zh) 2023-07-11

Similar Documents

Publication Publication Date Title
CN108137708B (zh) 人凝血因子ix融合蛋白及其制备方法与用途
JP7297837B2 (ja) Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
AU761027B2 (en) Expression and export of angiostatin and endostatin as immunofusis
AU2004239244B2 (en) Clotting factor-Fc chimeric proteins to treat hemophilia
RU2433181C2 (ru) Рекомбинантный слитый человеческий белок epo-fc с продленным временем полужизни и повышенной эритропоэтической активностью in vivo (варианты), димерная белковая конструкция, димерный белок, фармацевтическая композиция, последовательность нуклеиновой кислоты (варианты), вектор экспрессии, клетка, способ получения белка и способ стимуляции эритропоэза у млекопитающего
RU2722374C1 (ru) Высокогликозилированный слитый белок на основе фактора свертывания крови человека viii, способ его получения и его применение
CN105163751B (zh) 复合物
CN103739712A (zh) 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物
CN103397009B (zh) 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
CN104661674A (zh) 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
RU2620072C2 (ru) ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ
US10023624B2 (en) Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein
EA035323B1 (ru) Полипептиды химерного фактора viii и их применение
US11560436B2 (en) Anti-VWF D'D3 single-domain antibodies fuse to clotting factors
CN106279436A (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
JP2022118184A (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
CN114364796B (zh) 嵌合蛋白
KR20210141608A (ko) 치료요법에서 인자 ix 변이체 및 이의 용도
CN113646331A (zh) 单链因子viii分子
JP7305864B2 (ja) 改善されたｆｉｘ融合タンパク質、コンジュゲート及びその使用
CN103599527A (zh) 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
WO2017029129A1 (en) Heteromers with enzymatic activity
AU2012203896B2 (en) Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant